US EditionPublished • loading... • Updated
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
Takeda will pay Innovent $1.2 billion upfront with potential milestones totaling $10.2 billion to co-develop and commercialize next-gen immuno-oncology and antibody-drug conjugate therapies.
- Dec. 4, 2025, Innovent Biologics and Takeda closed a global strategic collaboration, effective after all closing conditions were met.
- The collaboration aims to accelerate global development and commercialization of Innovent's next-generation therapies, including an option on IBI3001, as announced recently.
- Under the financial terms, Takeda will pay Innovent US$1.2 billion upfront including a US$100 million equity investment at HK$112.56 per share, with a $11.4 billion total deal value and 40/60 Innovent/Takeda profit share for IBI363 in the U.S.
- Takeda will hold manufacturing rights for IBI363 outside Greater China, with co-exclusive U.S. supply rights with Innovent Biologics, while Innovent granted Takeda exclusive global rights for IBI343 outside Greater China.
- As a broader context, Innovent Biologics partners with over 30 global healthcare companies, has 1 new drug application under review, 4 assets in Phase 3, and 15 molecules in early clinical stage.
Insights by Ground AI
27 Articles
27 Articles
Takeda and Innovent fulfil close conditions for ADC and IO therapies
In October 2025, the two companies signed the deal as part of their focus on bispecifics and ADCs. The agreement aims to expedite the worldwide development and commercialisation The post Takeda and Innovent fulfil close conditions for ADC and IO therapies appeared first on Pharmaceutical Business review.
Coverage Details
Total News Sources27
Leaning Left2Leaning Right1Center14Last UpdatedBias Distribution82% Center
Bias Distribution
- 82% of the sources are Center
82% Center
12%
C 82%
Factuality
To view factuality data please Upgrade to Premium
